文献速递临床试验与 GCP基础与转化研究

评估腺病毒载体B群荚膜脑膜炎球菌疫苗安全性和免疫原性的1/2a期临床试验

A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine.
PubMed 文献 · Sci Transl Med · 2025-05-07

这项在18至50岁健康成人中开展的单中心1/2a期试验,评估了ChAdOx1 MenB.1疫苗单剂或两剂(第0天和第180天)及与4CMenB异源初免-加强方案的安全性。疫苗耐受良好,两剂后100%受试者产生针对表达同源fHbp变异株的保护性SBA滴度,但对异源fHbp菌株交叉反应低,提示可能需要多价疫苗。

要点

  • ChAdOx1 MenB.1耐受良好,无安全性担忧。
  • 两剂后100%受试者产生针对同源fHbp变异株的保护性SBA滴度。
  • 对表达异源fHbp菌株的SBA反应低,提示可能需要多价疫苗。

核心结论

  • ChAdOx1 MenB.1在人体中具有免疫原性,在该平台中加入另一种fHbp变异株或另一种抗原可能提供扩展针对地方性MenB疾病保护的方法。

研究设计与样本

  • 1/2a期单中心试验,纳入18至50岁健康成人,受试者在第0天和第180天接受一剂或两剂ChAdOx1 MenB.1,部分在第0天接受一剂4CMenB初免的个体在第180天接受一剂ChAdOx1 MenB.1。

主要发现

  • ChAdOx1 MenB.1耐受良好,无安全性担忧。
  • 两剂后100%受试者产生针对表达同源fHbp变异株MenB菌株的保护性SBA滴度。
  • 交叉反应分析显示对表达异源fHbp菌株的SBA反应低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Capsular group B meningococcus (MenB) remains an important cause of disease globally, and additional vaccines against MenB would aid in reducing the incidence of infection. Previous work has demonstrated that a MenB adenoviral-vectored vaccine, ChAdOx1 MenB.1, elicited high serum bactericidal responses in preclinical models after a single dose, supporting further clinical development of this vaccine. Here, we report the results of a trial designed to assess the safety and immunogenicity of ChAdOx1 MenB.1 in healthy adults aged 18 to 50. In this phase 1/2a, single-center trial, participants received one or two doses of ChAdOx1 MenB.1 at days 0 and 180. One dose of ChAdOx1 MenB.1 was also given at day 180 to some individuals primed with one dose of 4CMenB at day 0. Participants recorded their symptoms in an electronic diary after vaccination, and safety blood readouts were monitored. Serum bactericidal antibody (SBA) assays were performed against a panel of MenB target strains. ChAdOx1 MenB.1 was well tolerated with no safety concerns and elicited protective SBA titers against a MenB strain expressing a homologous factor H-binding protein (fHbp) variant in 100% of participants after two doses. However, cross-reactivity analysis indicated a low SBA response to strains expressing heterologous fHbp, suggesting that a multivalent vaccine may be needed. In sum, ChAdOx1 MenB.1 is immunogenic in humans, and addition of another fHbp variant or of another antigen in this platform could provide an approach to extend protection against endemic MenB disease.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Dold C, Oguti B, Silva-Reyes L, et al. A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine. Sci Transl Med. 2025. PMID: 40333993. doi:10.1126/scitranslmed.adn1441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。